Cargando…
Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives
Hepatocellular carcinoma (HCC) is a hypervascular malignancy and is the third leading cause of death worldwide. The disease has multiple predisposing risk factors and limited treatment options. Although the precise mechanism(s) underlying HCC is unknown, several pathways have been implicated in its...
Autores principales: | Bupathi, Manojkumar, Kaseb, Ahmed, Janku, Filip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211614/ https://www.ncbi.nlm.nih.gov/pubmed/25364263 http://dx.doi.org/10.2147/OTT.S46457 |
Ejemplares similares
-
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing
por: Janku, Filip, et al.
Publicado: (2014) -
Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma
por: Pestana, Roberto Carmagnani, et al.
Publicado: (2018) -
Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives
por: Bupathi, Manojkumar, et al.
Publicado: (2016) -
The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma
por: Vanderborght, Bart, et al.
Publicado: (2020) -
Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series
por: Bupathi, Manojkumar, et al.
Publicado: (2017)